Bio-Path Holdings is a focused RNAi nanoparticle drug development company utilizing a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Co.'s primary drug candidate, prexigebersen, is for the treatment of acute myeloid leukemia (AML) in combination with low-dose cytarabine and in combination with decitabine. Co.'s second drug candidate, Liposomal Bcl-2, targets the protein Bcl-2, which is responsible for driving cell survival in all cancers. Co.'s third drug candidate, Liposomal Stat3, targets the Stat3 protein and is a potential treatment for pancreatic cancer, non-small cell lung cancer and AML. The BPTH stock yearly return is shown above.
The yearly return on the BPTH stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the BPTH annual return calculation with any dividends reinvested as applicable (on ex-dates).
|